Open Access Repository

Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses


Downloads per month over past year

Tremlett, H, van der Mei, IAF, Pittas, F, Blizzard, CL, Paley, G, Dwyer, T, Taylor, BV and Ponsonby, AL (2008) Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiology and Drug Safety, 17 (6). pp. 565-576. ISSN 1053-8569

[img] PDF
Tremlett_Pharma...pdf | Request a copy
Full text restricted
Available under University of Tasmania Standard License.


Background Long-term immunomodulatory drug (IMD) treatment is now common in multiple sclerosis (MS). However,
predictors of adherence are not well understood; past studies lacked lifestyle factors such as alcohol use and predictors of
missed doses have not been evaluated. We examined both levels of non-adherence—stopping IMD and missing doses.
Methods This longitudinal prospective study followed a population-based cohort (n=199) of definite MS patients in
Southern Tasmania (January 2002 to April 2005, source population 226 559) every 6 months. Baseline factors (demographic,
clinical, psychological and cognitive) affecting adherence were examined by logistic regression and a longitudinal analysis
(generalized estimating equation (GEE)).
Results Of the 97 patients taking an IMD (mean follow-up=2.4 years), 73% (71/97) missed doses, with 1 in 10
missing>10 doses in any 6-month period. Missed doses were positively associated with alcohol amount consumed per
session ( p=0.008). A history of missed doses predicted future missed doses ( p<0.0005). Over one-quarter (27/97) stopped their current IMD, which was associated with lower education levels ( p=0.032) and previous relapses ( p=0.05). No
cognitive or psychological test predicted adherence.
Conclusions There were few strong predictors of missed doses, although people with MS consuming more alcoholic drinks
per session are at a higher risk of missing doses. Divergent factors influenced the two levels of non-adherence indicating
the need for a multifaceted approach to improving IMD adherence. In addition, missed doses should be assessed
and incorporated into clinical trial design and clinical practice as poor adherers could impact on clinical outcomes.

Item Type: Article
Authors/Creators:Tremlett, H and van der Mei, IAF and Pittas, F and Blizzard, CL and Paley, G and Dwyer, T and Taylor, BV and Ponsonby, AL
Keywords: multiple sclerosis; adherence; compliance; immunomodulatory treatment; beta-interferon; glatiramer acetate
Journal or Publication Title: Pharmacoepidemiology and Drug Safety
Page Range: pp. 565-576
ISSN: 1053-8569
Identification Number - DOI: 10.1002/pds.1593
Additional Information:

The definitive published version is available online at:

Date Deposited: 09 Dec 2008 22:23
Last Modified: 18 Nov 2014 03:54
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page